HAS2 and pulmonary arterial hypertension: HAS2 is a main component of most extracellular matrix and is associated with disease progression of experimental PAH, and inhibition of HAS2 can alleviate PAH and pulmonary fibrosis-related diseases (Collum et al., 2017).